Lundbeck Unveils Bexicaserin's Dual Mechanism at European Epilepsy Congress
Event summary
- Lundbeck to present preclinical data on bexicaserin's dual mode of action at the European Epilepsy Congress, September 5–9, 2026.
- Bexicaserin shown to increase inhibitory and decrease excitatory neuronal activity in preclinical models.
- Phase III DEEp Program evaluating bexicaserin for DEEs includes trials for Lennox-Gastaut syndrome and Dravet syndrome.
- FDA granted Breakthrough Therapy designation for bexicaserin in DEEs for patients aged 2 and older.
The big picture
Lundbeck's focus on bexicaserin underscores the unmet need for treatments in rare and severe epilepsies like DEEs. The dual mechanism of action could offer a broader antiseizure profile, addressing the heterogeneity of these conditions. The Phase III trials and regulatory designations highlight the strategic importance of this program in Lundbeck's neuroscience portfolio.
What we're watching
- Clinical Trial Progress
- The pace at which the Phase III DEEp Program delivers results will determine bexicaserin's regulatory pathway and commercial potential.
- Regulatory Dynamics
- Whether the Breakthrough Therapy designation will accelerate FDA approval and expand market access for bexicaserin.
- Competitive Landscape
- How Lundbeck's mechanistic insights on bexicaserin's dual mode of action will position it against existing and emerging treatments for DEEs.